Heranba Industries [HERANBA] vs Astec LifeSciences [ASTEC] Detailed Stock Comparison
Heranba Industries
NSE
Loading...
Astec LifeSciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Heranba Industries wins in 11 metrics, Astec LifeSciences wins in 7 metrics, with 0 ties. Heranba Industries appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Heranba Industries | Astec LifeSciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 417.08 | 399.52 | Astec LifeSciences |
| Price-to-Book Ratio | 1.59 | 7.12 | Heranba Industries |
| Debt-to-Equity Ratio | 41.05 | 235.96 | Heranba Industries |
| PEG Ratio | -6.57 | -22.88 | Astec LifeSciences |
| EV/EBITDA | 18.48 | -69.23 | Astec LifeSciences |
| Profit Margin (TTM) | -0.49% | -31.78% | Heranba Industries |
| Operating Margin (TTM) | 2.19% | -24.68% | Heranba Industries |
| EBITDA Margin (TTM) | 2.19% | N/A | N/A |
| Return on Equity | 0.36% | -57.34% | Heranba Industries |
| Return on Assets (TTM) | 0.17% | -15.29% | Heranba Industries |
| Free Cash Flow (TTM) | $-1.75B | $-302.21M | Astec LifeSciences |
| Dividend Yield | 0.44% | N/A | N/A |
| 1-Year Return | -31.04% | -28.43% | Astec LifeSciences |
| Price-to-Sales Ratio (TTM) | 0.86 | 4.71 | Heranba Industries |
| Enterprise Value | $16.38B | $22.22B | Astec LifeSciences |
| EV/Revenue Ratio | 1.05 | 5.51 | Heranba Industries |
| Gross Profit Margin (TTM) | 29.91% | 29.86% | Heranba Industries |
| Revenue per Share (TTM) | $393 | $206 | Heranba Industries |
| Earnings per Share (Diluted) | $-1.87 | $-64.81 | Heranba Industries |
| Beta (Stock Volatility) | 0.20 | 0.03 | Astec LifeSciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Heranba Industries vs Astec LifeSciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Heranba Industries | 0.12% | -4.63% | 0.68% | 16.61% | 47.63% | -22.01% |
| Astec LifeSciences | 2.41% | 0.91% | 10.19% | 6.73% | 21.89% | -11.92% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Heranba Industries | -31.04% | -41.34% | -59.05% | -59.05% | -59.05% | -59.05% |
| Astec LifeSciences | -28.43% | -54.80% | -30.61% | 266.69% | 973.73% | 949.67% |
News Based Sentiment: Heranba Industries vs Astec LifeSciences
Heranba Industries
News based Sentiment: NEGATIVE
September was a pivotal month for Heranba Industries, revealing a complex picture of strategic expansion juxtaposed with significant financial challenges and a 'going concern' warning from the auditor. While the company is actively investing in growth, the declining earnings, overvaluation, and auditor's opinion create substantial investor risks.
Astec LifeSciences
News based Sentiment: MIXED
Astec LifeSciences reported a decline in revenue alongside a slight increase in operating profit and a reduced net loss, creating a mixed financial picture. The appointment of a new director and the resignation of an existing one signal potential strategic changes, adding to the complexity of the investment story.
Performance & Financial Health Analysis: Heranba Industries vs Astec LifeSciences
| Metric | HERANBA | ASTEC |
|---|---|---|
| Market Information | ||
| Market Cap | ₹13.41B | ₹18.95B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 112,185 | 49,450 |
| 90 Day Avg. Volume | 133,527 | 54,241 |
| Last Close | ₹332.75 | ₹866.50 |
| 52 Week Range | ₹208.00 - ₹562.00 | ₹634.60 - ₹1,333.50 |
| % from 52W High | -40.79% | -35.02% |
| All-Time High | ₹945.00 (Mar 01, 2021) | ₹2,288.80 (Nov 14, 2022) |
| % from All-Time High | -64.79% | -62.14% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.53% | 0.31% |
| Quarterly Earnings Growth | -0.64% | 0.31% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.32% |
| Operating Margin (TTM) | 0.02% | -0.25% |
| Return on Equity (TTM) | 0.00% | -0.57% |
| Debt to Equity (MRQ) | 41.05 | 235.96 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹210.15 | ₹119.70 |
| Cash per Share (MRQ) | ₹13.69 | ₹0.29 |
| Operating Cash Flow (TTM) | ₹-1,237,700,000 | ₹-705,500,000 |
| Levered Free Cash Flow (TTM) | ₹30.70M | ₹-1,347,524,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.44% | N/A |
| Last 12-Month Dividend | ₹1.25 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Heranba Industries vs Astec LifeSciences
| Metric | HERANBA | ASTEC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 417.08 | 399.52 |
| Forward P/E | N/A | 21.10 |
| PEG Ratio | -6.57 | -22.88 |
| Price to Sales (TTM) | 0.86 | 4.71 |
| Price to Book (MRQ) | 1.59 | 7.12 |
| Market Capitalization | ||
| Market Capitalization | ₹13.41B | ₹18.95B |
| Enterprise Value | ₹16.38B | ₹22.22B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.05 | 5.51 |
| Enterprise to EBITDA | 18.48 | -69.23 |
| Risk & Other Metrics | ||
| Beta | 0.20 | 0.03 |
| Book Value per Share (MRQ) | ₹210.15 | ₹119.70 |
Financial Statements Comparison: Heranba Industries vs Astec LifeSciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HERANBA | ASTEC |
|---|---|---|
| Revenue/Sales | ₹3.35B | ₹910.82M |
| Cost of Goods Sold | ₹2.43B | ₹638.84M |
| Gross Profit | ₹922.60M | ₹271.98M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-300.60M | ₹-224.80M |
| EBITDA | ₹-113.70M | ₹-104.80M |
| Pre-Tax Income | ₹-411.40M | ₹-330.18M |
| Income Tax | ₹5.30M | ₹94,000 |
| Net Income (Profit) | ₹-416.70M | ₹-330.27M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HERANBA | ASTEC |
|---|---|---|
| Cash & Equivalents | ₹425.90M | ₹5.75M |
| Total Current Assets | ₹10.33B | ₹3.41B |
| Total Current Liabilities | ₹8.60B | ₹3.66B |
| Long-Term Debt | ₹959.80M | ₹2.80B |
| Total Shareholders Equity | ₹8.50B | ₹2.35B |
| Retained Earnings | N/A | ₹1.41B |
| Property, Plant & Equipment | ₹6.62B | ₹317.38M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HERANBA | ASTEC |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | HERANBA | ASTEC |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 112,185 | 49,450 |
| Average Daily Volume (90 Day) | 133,527 | 54,241 |
| Shares Outstanding | 40.01M | 19.76M |
| Float Shares | 9.51M | 6.74M |
| % Held by Insiders | 0.76% | 0.84% |
| % Held by Institutions | 0.00% | 0.07% |
Dividend Analysis & Yield Comparison: Heranba Industries vs Astec LifeSciences
| Metric | HERANBA | ASTEC |
|---|---|---|
| Last 12-Month Dividend | ₹1.25 | ₹0.00 |
| Last 12-Month Dividend Yield | 0.44% | N/A |
| 3-Year Avg Annual Dividend | ₹1.50 | ₹1.00 |
| 3-Year Avg Dividend Yield | 0.32% | 0.10% |
| 3-Year Total Dividends | ₹4.50 | ₹3.00 |
| Ex-Dividend Date | Sep 05, 2024 | Jul 21, 2023 |